

FIG. 1. Bioconversion (% radiochemical yields) of factors II and III, (and their 3 and 8 epimers) derived from labeled ALA and AdoMet and of factor IV into cobyrinic acid (5) using cell-free extracts of *Pr. shermanii*. Labeling patterns were derived from either stable isotopes (●, [4-<sup>13</sup>C]ALA; ■, [5-<sup>13</sup>C]ALA; \*, [methyl-<sup>13</sup>C]AdoMet) or radioisotopes (●, [4-<sup>14</sup>C]ALA; \*, [methyl-<sup>3</sup>H]AdoMet) as described in the text. The intermediates are isolated as methyl esters and reincubated (after hydrolysis) in their oxidized forms (factors II–IV) but it is assumed that the biotransformations occur at the reduced (pre-corrin) level since precorrin-2 can be isolated anaerobically from *Pr. shermanii* (9).

**Bioconversion of Factor II, (3β,8β-epi) Factor II, and Factor IV to Cobyrinic Acid.** Doubly labeled factors were prepared as described previously (5) from [5-<sup>14</sup>C]ALA and C<sup>3</sup>H<sub>3</sub>-AdoMet. Cobester was isolated from incubation of cell-free extract with the radiolabeled factors and chromatographed to constant radioactivity. The radio incorporations were determined by <sup>14</sup>C/<sup>13</sup>H scintillation counting, and the results are summarized in Fig. 1.

**NMR Correlations of Factor IV.** <sup>13</sup>C-chemical shifts, heteronuclear multiple bond, and heteronuclear multiple quantum correlations were acquired exactly as described for the structure determination of precorrin-3x (8). The assignments are summarized in Table 1.

## RESULTS AND DISCUSSION


Factor IV (4) was isolated from cell-free extracts of *Pr. shermanii* by esterification (MeOH/H<sub>2</sub>SO<sub>4</sub>) and multiple thin-layer chromatography. The presence of four methyl groups was deduced by the <sup>3</sup>H/<sup>14</sup>C ratios of specimens derived from [methyl-<sup>3</sup>H<sub>3</sub>]-AdoMet and either <sup>14</sup>C factor II (2) or <sup>14</sup>C factor III (3) (Fig. 1, \* = <sup>3</sup>H; ● = <sup>14</sup>C). Mass spectral analysis of the esters prepared from both MeOH (*m/z* 1046) and EtOH (*m/z* = 1144) revealed that seven ester groups were present (M + 98 for the ethyl analog); the eighth carboxylic function was a δ-lactone (FTIR: 1740 cm<sup>-1</sup>). When factor IV was isolated from incubations using [4-<sup>13</sup>C]ALA (1) and [methyl-<sup>13</sup>C]AdoMet as substrates, one-dimensional <sup>13</sup>C-NMR analysis (see Table 1) of the resultant <sup>13</sup>C-enriched heptamethyl ester (Fig. 1, factor IV 4: A = CH<sub>2</sub>CO<sub>2</sub>Me; P = CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Me; ● = <sup>13</sup>C) showed characteristic C-C coupling (*J* = 58 Hz) between C-19 and C-1, which is evidence that ring contraction

Table 1. <sup>13</sup>C NMR assignments of factor IV heptamethyl ester in benzene-d<sub>6</sub>

Position enriched	<sup>δ</sup> <sup>13</sup> C ( <i>J</i> cc Hz)
From [5- <sup>13</sup> C]ALA	
C4	178.0 (68)
C5	96.6 (69)
C9	177.5 (65)
C10	95.2 (65)
C14	151.8 (75)
C15	99.8 (75, 69)
C16	173.0 (69)
C20	81.9 (38)
From [4- <sup>13</sup> C]ALA	
C1	83.4 (57.8)
C3	60.16
C6	171.76
C8	55.7
C11	157.86
C13	146.68
C17	64.0 (33)
C19	151.4 (58.2)
Methyl groups from <sup>13</sup> CH <sub>3</sub> -AdoMet	
C2	20.13
C7	27.27
C17	21.26 (33)
C20	18.77 (38)

had occurred, whereas coupling (*J* = 33 Hz) between one of the four AdoMet-derived methyl groups and a *propionate* terminus ( $\delta$  64.0) suggested C-methylation at C-17. The observation of coupled doublets (*J* = 38 Hz) at  $\delta$  81.9 and 18.8 ppm in factor IV enriched from [5-<sup>13</sup>C]ALA and <sup>13</sup>C-AdoMet (Fig. 1, ■ and \* = <sup>13</sup>C) indicates that C-20 and its attached methyl group are still present in the molecule. Further NMR analyses (distortionless enhancement for polarization transfer, heteronuclear multiple quantum correlation, heteronuclear multiple bond correlation) disclose that C-20 is appended to C-1, and bears a proton, a methyl group, and the oxygen terminus of the δ-lactone as the fourth substituent. The assignment of methyl resonances at  $\delta$  20.1 and  $\delta$  27.3 ppm to C-2 and C-7, respectively, reveals that while C-3 is in the natural (α) configuration, the C-8 propionate is β-oriented, thereby releasing the γ-effect on the adjacent C-7 methyl, a well-known phenomenon in such epimerizations (10, 11).

Incubation of <sup>14</sup>C-labeled factor IV [biosynthesized from a mixture of 3-epi and 8-epi factor II (2a) with *Pr. shermanii* extracts] affords cobyrinic acid (5, isolated as cobester; A = CH<sub>2</sub>CO<sub>2</sub>Me; P = CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Me) in 0.6% radiochemical yield [Fig. 1, (4) → (5)]. Epimerization at C-8 of factor II has obviously caused derailment, thereby allowing isolation of 8β-configured factor IV, which is partially reepimerized to the natural (3α, 8α) isomer to allow synthesis of (5), confirmed by conversion of a mixture of 3-epi and 8-epi factor II (2a) directly to cobyrinic acid (5) in a comparable 1.7% radiochemical yield, together with a substantial amount of 8-epi factor IV. Indirect evidence for inversion of stereochemistry at C-8 had previously been observed by the exchange of H for D at C-3, C-8, and C-13 when vitamin B<sub>12</sub> was isolated from *Pr. shermanii* cells grown in 50% <sup>2</sup>H<sub>2</sub>O (12). Factor IV, whose absolute stereochemistry at C-2, C-7, and C-17 follows from bioconversion to cobyrinic acid, has been oxidized during isolation, and like factor II must be reduced by enzyme(s) present in the cell-free extract (1, 2, 9) to the precorrin-4 oxidation level (Scheme II) and then epimerized at C-8 to allow incorporation to proceed. It should be noted that precorrin-2 and -3 were first isolated in their oxidized forms, factors II and III, respectively, and are reduced back to the corresponding precorrins by reductive enzyme(s)



present in the cell-free extracts of *Pr. shermanii* and thus reenter the biosynthetic pathway (9).

A mechanism for the formation of factor IV is proposed in Scheme I and features  $\delta$ -lactone formation at C-20 that delivers the oxygen required for subsequent loss of the "C<sub>2</sub>" unit. Formation of a  $\delta$ -lactone from the ring A acetate to the C-20 position was first promulgated by Eschenmoser (13) as a means of functionalizing C-20 prior to ring contraction and as part of a scaffolding device for the ring contraction process. The discovery of the "aerobic" mechanism in which molecular oxygen serves as the source of the C-20 hydroxyl in precorrin-3x (=3B) (Scheme I) led Eschenmoser to suggest recently (14) that involvement of the  $\delta$ -lactone, however attractive as a chemical model, would probably require an oxidative step. The new structure of factor IV, together with the experimental demonstration of the transfer of <sup>18</sup>O from the ring A carboxylate to the acetic acid isolated in the anaerobic pathway (15) and the loss of <sup>18</sup>O from the same carboxylate function (6, 7), now provide strong support for the renaissance of the nonoxidative " $\delta$ -lactone" hypothesis, although not quite in its original form. The ring contraction takes place by a mechanism that may involve a cyclopropane intermediate followed by ring opening to forge the A-D ring linkage, leaving the pendant C-20 at the oxidation level of acetaldehyde. Thirty years ago, before the origin (AdoMet) of the C-1 methyl group of B<sub>12</sub> was discovered, Eschenmoser and colleagues (16, 17) had envisaged a cyclopropane intermediate formed by proton catalyzed reduction at the 20-meso position as part of the ring contraction process. Again, Eschenmoser (14) has referred to the "death of this cherished hypothesis" when the origin of the C-1 methyl group of B<sub>12</sub> was found to be methionine (2) rather than the C-20 meso carbon. The biosynthesis of factor IV may indeed involve just such a cyclopropane intermediate (Scheme I), which subsequently loses C-20 as acetaldehyde ( $\rightarrow$  acetic acid), thereby reviving one of the earliest concepts for ring contraction. Several alternatives remain, including proton catalyzed ring closure of a seco-corrinoid (18, 19). Thus, in cobalt precorrin-4 (Scheme II) the ring contraction is orches-

trated not by molecular oxygen, but by internal delivery of oxygen functionality that in turn could be mediated by remote interaction of cobalt with the carboxylate function in ring A and/or addition of the fourth C-methyl group in ring D at position 17 or 18. The latter position is favored stereoelectronically but would require subsequent migration of the methyl to C-17, just as is found for C-11  $\rightarrow$  C-12 methyl shift in the aerobic pathway. Subsequent hydrolysis of the  $\delta$ -lactone rationalizes the specific exchange of <sup>18</sup>O at C-27 (6, 7) and the transfer of <sup>18</sup>O to C-20 (15) and is coupled with retro-aldol release of acetaldehyde [from the putative Co-precorrin-5 (Scheme II)]. The excision of acetaldehyde requires revision of a previous mechanism (20, 21) based on loss of acetic acid, and would also necessitate a subsequent enzyme-catalyzed oxidation of the liberated acetaldehyde to acetic acid, which was isolated from *Pr. shermanii* extracts fed with <sup>14</sup>C-labeled precursors (20, 21). Conclusive evidence for this scenario is provided in the accompanying paper by Wang *et al.* (22).

The suggested anaerobic pathway to B<sub>12</sub> is shown in Scheme II where it is assumed that the two pathways converge at precorrin-6x (23). Verification must await the discovery of the appropriate biosynthetic enzymes by analysis of a genomic library of *Pr. shermanii* from which the first methyl transferase (CobA) has recently been isolated (24). The unique structure of factor IV adds strength to the postulate that all of the anaerobic intermediates from precorrin -2 onward are cobalt complexes (5, 25) and explains why attempts to elicit the appropriate enzyme activities from cloned *Salmonella* genes (26) that are responsible for corrin synthesis have so far been unsuccessful using cobalt-free substrates, although some crossover between the aerobic, metal-free intermediates precorrin -6x and -8x was observed when these were incorporated (albeit in low yield) into cobyric acid in cell-free extracts of *Pr. shermanii* (23).

We thank Prof. A. Eschenmoser for an enlightening discussion of the proposed mechanism. This work was supported by the National Institutes of Health, the Robert A. Welch Foundation (grant to A.I.S.), and the Deutsche Forschungsgemeinschaft (grant to G.M.).

- Blanche, F., Cameron, B., Crouzet, J., Debussche, L., Thibaut, D., Vuilhorgne, M., Leeper, F. J. & Battersby, A. R. (1995) *Angew. Chem. Int. Ed. Engl.* **34**, 383–411.
- Scott, A. I. (1994) *Tetrahedron* **50**, 13315–13334.
- Scott, A. I. (1994) *Heterocycles* **39**, 471–476.
- Spencer, J. B., Stolowich, N. J., Roessner, C. A., Min, C. & Scott, A. I. (1993) *J. Am. Chem. Soc.* **115**, 11610–11611.
- Müller, G., Zipfel, F., Hlineny, K., Savvidis, E., Hertle, R., Traub-Eberhard, V., Scott, A. I., Williams, H. J., Stolowich, N. J., Santander, P. J., Warren, M. J., Blanche, F. & Thibaut, D. (1994) *J. Am. Chem. Soc.* **113**, 9893–9895.
- Scott, A. I., Stolowich, N. J., Atshaves, B. P., Karuso, P., Warren, M. J., Williams, H. J., Kajiwara, M., Kuramaya, K. & Okazaki, T. (1991) *J. Am. Chem. Soc.* **113**, 9891–9892.
- Vishwakarma, R. A., Balachandran, S., Alanine, A. I. D., Stamford, N. P. J., Kuichi, F., Leeper, F. J. & Battersby, A. R. (1993) *J. Chem. Soc. Perkin Trans. 1* 2893–2898.
- Stolowich, N. J., Wang, J., Spencer, J. B., Roessner, C. A., Santander, P. J. & Scott, A. I. (1996) *J. Am. Chem. Soc.* **118**, 1657–1662.
- Battersby, A. R., Frobel, K., Hammerschmidt, F. & Jones, C. (1982) *J. Chem. Soc. Chem. Commun.* 455–458.
- Scott, A. I., Townsend, C. A. & Cushley, R. J. (1973) *J. Am. Chem. Soc.* **95**, 5759–5761.
- Battersby, A. R., McDonald, E., Neier, R. & Thompson, M. (1979) *J. Chem. Soc. Chem. Commun.* 960–962.
- Scott, A. I., Kajiwara, M. & Santander, P. J. (1987) *Proc. Natl. Acad. Sci. USA* **84**, 6616–6620.
- Eschenmoser, A. (1988) *Angew. Chem. Int. Ed. Engl.* **27**, 5–39.
- Eschenmoser, A. (1994) *CIBA Found. Symp.* **180**, 310–323.
- Arigoni, D. (1994) *CIBA Found. Symp.* **180**, 280–281.
- Wehrli, P. (1967) Ph.D. dissertation (Eidgenössische Technische Hochschule, Zurich).

17. Muller, P. M., Farooq, S., Hardegger, B., Salmond, W. S. & Eschenmoser, A. (1973) *Angew. Chem. Int. Ed. Engl.* **12**, 914–916.
18. Yamada, Y., Miljkovic, D., Wehrli, P., Golding, B., Lölliger, P., Keese, R., Müller, K. & Eschenmoser, A. (1969) *Angew. Chem. Int. Ed. Engl.* **8**, 343–348.
19. Ofner, S., Rasetti, V., Zehnder, B. & Eschenmoser, A. (1981) *Helv. Chim. Acta* **64**, 1431–1443.
20. Mombelli, L., Nussbaumer, C., Weber, H., Müller, G. & Arigoni, D. (1981) *Proc. Natl. Acad. Sci. USA* **78**, 9–10.
21. Battersby, A. R., Bushell, M. J., Jones, C., Lewis, N. G. & Pfenninger, A. (1981) *Proc. Natl. Acad. Sci. USA* **78**, 13–15.
22. Wang, J., Stolowich, N. I., Santander, P. J. & Scott, A. I. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 14320–14322.
23. Blanche, F., Thibaut, D., Debussche, L., Hertle, R., Zipfel, F. & Müller, G. (1993) *Angew. Chem. Int. Ed. Engl.* **32**, 1651–1653.
24. Sattler, I., Roessner, C. A., Stolowich, N. J., Hardin, S. H., Harris-Haller, L. W., Yokubaitis, N. T., Murooka, Y., Hashimoto, Y. & Scott, A. I. (1995) *J. Bacteriol.* **177**, 1564–1569.
25. Balachandran, S., Vishwakarma, R. A., Monaghan, S. M., Prella, A., Stamford, N. P. J., Leeper, F. J. & Battersby, A. R. (1994) *J. Chem. Soc. Perkin Trans. 1* 487–491.
26. Roessner, C. A., Warren, M. J., Santander, P. J., Atshaves, B. P., Ozaki, S.-I., Stolowich, N. J., Iida, K. & Scott, A. I. (1992) *FEBS Lett.* **301**, 73–78.